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Gaucher’s disease (GD) is the most prevalent lysosomal storage disorder. GD is caused
by homozygous mutations of the GBA1 gene, which codes for beta-glucocerebrosidase
(GCase). Although GD primarily affects peripheral tissues, the presence of neurological
symptoms has been reported in several GD subtypes. GBA1 mutations have
recently deserved increased attention upon the demonstration that both homo- and
heterozygous GBA1 mutations represent the most important genetic risk factor for the
appearance of synucleinopathies like Parkinson’s disease (PD) and dementia with Lewy
bodies (LBD). Although reduced GCase activity leads to alpha-synuclein aggregation,
the mechanisms sustaining a role for GCase in alpha-synuclein homeostasis still
remain largely unknown. Furthermore, the role to be played by impairment in the
physiological function of endoplasmic reticulum, mitochondria and other subcellular
membranous components is currently under investigation. Here we focus on the impact
of GCase loss-of-function that impact on the levels of sterylglucosides, molecules
that are known to trigger a PD-related synucleinopathy upon administration in rats.
Moreover, the concurrence of another gene also coding for an enzyme with GCase
activity (GBA2 gene) should also be taken into consideration, bearing in mind that
in addition to a hydrolytic function, both GCases also share transglycosylation as a
second catalytic activity. Accordingly, sterylglycoside levels should also be considered
to further assess their impact on the neurodegenerative process. In this regard—and
besides GBA1 genotyping—we suggest that screening for GBA2 mutations should be
considered, together with analytical measurements of cholesterol glycosides in body
fluids, as biomarkers for both PD risk and disease progression.
Keywords: GBA1, GCase, alpha-synuclein, lysosome, Parkinson’s disease, dementia with Lewy bodies,
neurodegenerative disease
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INTRODUCTION
Glucocerebrosidases (GCases) catalyze the hydrolysis of
D-glucosyl-N-acylsphingosine to D-glucose and
N-acylsphingosine (E.C. enzyme entry: 3.2.1.45) and,
therefore, the systematic name is D-glucosyl-N-acylsphingosine
glucohydrolase. They may also catalyze the hydrolysis of
other sugar derivatives, i.e., of Glycosyl-N-acylsphingosine to
N-acylsphingosine and the corresponding sugar (E.C. enzyme
entry: 3.2.1.62). Further enzyme activities have been described for
GCases, thus showing that they have broad substrate specificity.
For instance, according to the IUBMB enzyme nomenclature
database1, they may display lactase activity (lactase hydrolysis to
glucose and galactose; EC enzyme entry: 3.2.1.108).
GBA1 ß-glucosylceramidase gene is located in 1q22 of
chromosome 1 of the human genome (Gene ID: 2629) and its
gene product is a lysosomal enzyme with GCase activity. GBA2
ß-glucosylceramidase gene is located in 9p13.3 of chromosome
9 of the human genome (Gene ID: 57704, updated on Oct-2017)
and also encodes for a protein with GCase activity. The product
of the GBA2 gene was discovered long time ago by van Weely
et al. (1993), who demonstrated that, unlike the firstly-described
GCase, the product of the GBA2 gene was non-lysosomal, weakly
associated to membranes and unrelated to Gaucher’s disease
(GD; Figure 1). Identification of the gene and confirmation of
the main characteristics of the gene products were achieved and
reported years later by Boot et al. (2007).
THE GENETIC LINK BETWEEN
GBA1 GENE MUTATIONS AND
SYNUCLEINOPATHIES
Since a first case-report published in 1939 (Van Bogaert, 1939),
more convincing evidence showing an association of GD and
Parkinson’s disease (PD) was provided byNeudorfer et al. (1996),
who reported six GD patients exhibiting ‘‘typical extrapyramidal
symptoms’’ such as tremor, rigidity and bradykinesia. Later
on, multicenter studies recruiting several thousands of patients
revealed that GBA1 mutations are the most common genetic
risk factor for developing PD (Sidransky et al., 2009; Velayati
et al., 2010) In fact, a marked incidence of GBA1 mutations
has been found in familial forms of PD (Mitsui et al., 2009;
Nichols et al., 2009) as well as in up to 17% of PD patients that
underwent deep brain stimulation (Angeli et al., 2013). Overall, it
has been estimated that some GBA1 mutations may increase 20-
to 30-fold the PD risk (Spitz et al., 2008; Sidransky et al., 2009;
Bultron et al., 2010; McNeill et al., 2012; Mao et al., 2013; Blanz
and Saftig, 2016; Migdalska-Richards and Schapira, 2016; Aflaki
et al., 2017; O’Regan et al., 2017; Standaert, 2017). Moreover,
the association of GBA1 mutations and dementia with Lewy
bodies (LBD) is even stronger than for PD (Mata et al., 2008;
Nalls et al., 2013). The association between GBA1 mutations and
synucleinopathies other than PD and dementia with LBD, such
as multiple system atrophy, still remains controversial (Asselta
1www.sbcs.qmul.ac.uk/iubmb/enzyme/
et al., 2014; Sklerov et al., 2017). A further interesting fact is
that the type of mutations may increase the risk of one given
synucleinopathy. In this regard and considering the two most
frequent GBA1 mutations—L444P and N370S—the latter been
regarded as more closely related to PD, whereas the L444P
mutation seems to be more likely associated with LBD (Cilia
et al., 2016). That said, it is also worth noting that PD and DLB
share together a number of clinical and pathological features and
indeed these clinical entities can even be considered as very close
diseases (Friedman, 2018).
Regarding clinical phenotype, the onset occurs earlier in
PD patients carrying a GBA1 mutation but the symptoms
and efficacy of anti-PD medication is similar to those in
idiopathic patients (Blanz and Saftig, 2016; Migdalska-Richards
and Schapira, 2016; Aflaki et al., 2017). GBA1 mutation
carriers are, however, more frequently affected by cognitive
deficits and neuropsychiatric symptoms. Furthermore,
the neuropathological fingerprint of Gaucher’s-associated
PD is very similar to PD without GBA1 gene mutations,
both conditions showing different age at death but no
differences in ‘‘total or regional semi-quantitative scores for
Lewy-type synucleinopathy, senile plaques, neurofibrillary
tangles, white matter rarefaction or cerebral amyloid
angiopathy scores’’ (Adler et al., 2017). Hence, it is tempting
to speculate that GCase activity is a common underlying
factor triggering alpha-synuclein-induced neurodegenerative
processes in both GBA1 mutation carrier and non-carrier PD
patients.
GCase GAIN- AND LOSS-OF-FUNCTION
ALTERNATIVES
The mechanisms by which GBA1 mutations could lead to
PD were assessed by Velayati et al. (2010) who were, to
our knowledge, the first to suggest that α-synuclein was at
the center stage. The authors hypothesized that aggregation
of α-synuclein was occurring either by ‘‘enhanced protein
aggregation or as a consequence of glucocerebrosidase deficiency.’’
Authors also analyzed the two canonical alternative possibilities,
i.e., that the disease could derive from a loss-of-function or
a gain-of-function of GCase activity. Authors suggested that
GCase gain-of function could explain deficits in proteostasis by
the proteasome, endoplasmic reticulum stress and autophagy
engagement. Since then, other authors have reinforced the idea
that GBA1 mutations contribute to alpha-synuclein aggregation
and engagement of autophagy and lysosome-mediated processes
(GCase is a lysosomal enzyme; Westbroek et al., 2011;
Beavan and Schapira, 2013; Dehay et al., 2013; Manzoni
and Lewis, 2013; Pan and Yue, 2014; Zhang et al., 2014;
Magalhaes et al., 2016; García-Sanz et al., 2018; Kinghorn et al.,
2017).
It should be noted that congenital diseases involving enzymes
are almost exclusively due to a loss of function (Scriver et al.,
2001). After millions of years of evolution, it is not impossible
but unlikely that a mutant enzyme leads to a gain of function, at
the very least in what concerns the catalytic activity. In almost any
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inherited disease caused by mutations in the gene for any given
enzyme, the activity is at the center stage and GCase is not an
exception to this general rule. Indeed, it is broadly assumed that
GD is due to reduced GCase activity, with a residual 32%–38%
enzymatic activity accounting for GD type 1 (non-neuropathic
GD), down to 13%–24% of reduced activity when considering
neuropathic GD types 2 and 3 (Malini et al., 2014). Recent
reports in the Drosophila model provide more complexity to
the link between GCase activity and proteinopathies resulting
in neuronal death. In one of them GCase deficient flies show
protein aggregation and neurodegeneration but unrelated to α-
synuclein (Davis et al., 2016). In the second, silencing the GBA
gene affects locomotion by enhancing the aggregation of the
PD-associated A73T α-synuclein gene mutant (Abul Khair et al.,
2018).
In some cases, clinical symptoms appear only in homozygous
states when GCase enzymatic activity is nearly zero. GD patients
express mutant proteins displaying very diverse activity when
measured as terms of GCase. On looking at clinical parameters
from different patients it is assumed that the different GCase
activity is the cause of the huge variety of symptoms involving
different tissues and with varied intensity. For instance, the
E326K PD-associated GCase1 variant (Berge-Seidl et al., 2017)
may manifest GD subtypes 1, 2 or 3. It should be noted that
there was controversy on whether it was a mutation or a
polymorphism, as its presence in GD patients was accompanied
with other GCase mutants (Park et al., 2002). Type 1 is
characterized with the absence of neurological alterations, type
3 courses with signs of neurological disturbances and type
2 also courses with neurological alterations but severe and
with early-appearing clinical symptoms, even at 3-months of
age (Scriver et al., 2001; Horowitz et al., 2011). Being obvious
that alterations of a lysosomal enzyme may influence the
handling of proteins such as synucleins and, ultimately, engage
autophagy, it is surely necessary to emit hypotheses aimed to
better understand how a reduced enzyme activity may affect
neuronal fate.
REDUCED GCase ACTIVITY MAY LEAD TO
NEUROTOXIC LEVELS OF STEROL
GLYCOSIDES
Cholesterol and its derivatives are key molecules for the
life of higher animal organisms. Cholesterol homeostasis is
fundamental in a myriad of molecular processes ranging
from membrane integrity to neurotransmission. Then, any
alteration in the activity of the enzymes handling cholesterol
should be taken into consideration. In this regard, while the
presence of cholesterol has been widely studied, identification
and distribution of cholesterol derivatives in subcellular
compartments and, more importantly, of their function is largely
incomplete (to date). Besides the classical neurotoxin-based
rodent and primate models of PD (6-OHDA and MPTP), a
new model has been recently developed. This model stands
on the administration—to rats—of β-sitosterol β-D-glucoside
(BSSG) leading to a progressive model of the disease. One of
the many relevant features of the model is that, unlike other
PD animal models, it leads to the accumulation of aggregated
alpha-synuclein closely mimicking LBD (Van Kampen et al.,
2015; Van Kampen and Robertson, 2017). These findings lead
to hypothesize that accumulation of endogenous sterylglycosides
may be neurotoxic for dopaminergic neurons. Reduced activity
of GCase leads to increased levels of glucosylated lipids and of
cholesterol and its esters (Magalhaes et al., 2016; Galvagnion,
2017). In fact, it has been recently found in fibroblasts
from parkinsonian patients that the N370S-GBA1 mutation
leads to lysosomal accumulation of cholesterol (García-Sanz
et al., 2017). Also interesting is the recent elucidation of
the structure of lipid-bound luminal domain of lysosomal
integral membrane protein-2 (LIMP-2), which acts as a GCase
receptor that allows trafficking of the enzyme from the
endoplasmic reticulum to lysosomes, where it participates in
sphingolipid processing (Reczek et al., 2007). Depending on the
interaction with phospholipids and cholesterol, LIMP-2 shifts
from a glucocerebrosidase-binding monomer to a dimer with
differential lipid-exchange potential (Conrad et al., 2017).
It has been confirmed that GCase may display a second
catalytic activity, namely glucosyltransferase (GCase1-t in
Figure 1). Such chemical activity consists of transglucosylation,
resulting in the transfer of the carbohydrate moiety from
glucosylceramide (GlcCer) to cholesterol to form β-cholesteryl
glucoside (GlcChol; Figure 1). Reversible transfer of a glucose
moiety (transglucosylation) between GlcChol and GlcCer is
catalyzed by GCase (Marques et al., 2016). Although the in vivo
regulation of transglucosylation remains unknown, evidence
shows that in non-pathological conditions GCase hydrolytic
activity (GCase1-h in Figure 1) promotes the degradation of
GlcChol. Mutant GCase could then be a factor promoting
increased levels of GlcChol.
Analysis of sterylglucoside composition in the mammalian
brain suggests a heterogeneous composition that includes the β-
sitosterylglucoside (Akiyama andHirabayashi, 2017). The above-
described consequences of BSSG administration fits well with the
finding that steryl-β-glucoside (ASG) contained in Cycad seeds
directly enhances in vitro aggregation and cytotoxicity of alpha-
synuclein (Van Kampen et al., 2015). Interestingly, inhabitants
of Guam archipelago suffer from a severe syndrome apparently
triggered by β-sitosterylglucoside accumulation after ingestion
of Cycad plant-seed-derived products. The degenerative disease
is known as ALS-PDC due to symptoms of amyotrophic
lateral sclerosis and/or of the so-called parkinsonism/dementia
complex (Shaw et al., 2002; Steele and McGeer, 2008). In
keeping with neurotoxicity after consumption (Khabazian
et al., 2002; Tabata et al., 2008), both neurotoxicity and
links with PD have been confirmed by showing in rats
that the synthetic β-sitosterylglucoside leads to a progressive
parkinsonism whose clinical and histopathology scores may
be sustained over the time and continue after cessation of
the neurotoxic insult (Van Kampen et al., 2015). Due to the
relatively poor specificity of GCase (see above) it is likely
that the enzyme may use O-linked glycosides as substrates.
Glucose binds to sitosterol in a similar manner that it binds
to ceramide (Ivorra et al., 1988). Reduced GCase activity
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FIGURE 1 | Differential action of enzymes encoded by GBA1 and GBA2 genes in the endoplasmic reticulum and in lysosomes. The nomenclature for
GBA1-encoded and GBA-2-encoded enzymes is, respectively, GCase1 and GCase2. In both enzymes hydrolase activity is denoted with a terminal “h” and
transferase activity with a terminal “t”.
could then lead to accumulation of steryl-glycoside neurotoxic
compounds.
BOTH THE ß-GLUCOSIDASE ACTIVITY
AND GLUCOSYL CHOLESTEROL
DESERVE ATTENTION IN PD
Regarding PD, the development in a rodent model of a
progressive parkinsonian phenotype by β-sitosterylglucoside
is in full keeping with the finding that ASG contained in
Cycad seeds directly enhances the in vitro aggregation and
cytotoxicity of alpha-synuclein (Van Kampen et al., 2015). By
using electrospray ionization mass Spectrometry (ESI-MS/MS)
assays, ß-glucosyl-cholesterol (GlcChol) has been detected in
body fluids and tissues, including the central nervous system
(CNS; Marques et al., 2016). Since the chromatographic behavior
of galactosylceramide (GalCer), which is abundant in the CNS,
is similar to that of GlcChol, it has been a technical challenge
the assessment of GlcChol identification and quantitation in
brain samples. There is no doubt now that GlcChol is present
in the vertebrate brain. The compound is also detectable in blood
plasma and, therefore, it is one of the parameters that might be
followed in PD patients. It should be noted that (Marques et al.,
2016) have reported that GlcChol plasma levels are higher in
symptomatic GD patients.
Several in vitro examples of alterations due to unbalanced
levels of sterol derivatives have been made available in
the literature. For instance GlcChol regulates heat shock
and stress response in vitro (Kunimoto et al., 2000, 2002).
Exposure of fibroblasts to the compound induces rapid
activation of heat shock transcription factor 1, binding to
heat shock element and induction of heat shock protein
70, thus showing GlcChol as a significant mediator of
stress responses. In in vitro cultures of NSC34 cells, which
constitute a motoneuron cell model, low concentrations of
GlcChol is neuroprotective whereas chronic exposure to
GlcChol, i.e., in conditions resulting from defects on GCase-
driven transglucosylation, results in neurotoxicity (Ly et al.,
2008).




In the context of common features shared by GD and PD,
hydrolysis has been the only activity that has been considered
(Futerman and Hardy, 2016). GBA2 is a second gene that
encodes a protein that, similarly to that encoded by GBA1 has
two activities: hydrolysis (GCase) and the glucosyl transfer.
The additional transglucosylation activity of enzymes coded by
GBA1 and GBA2, their role in regulating the concentration
of sterylglucosides and the different subcellular localization
of the different GCases should be kept in mind to properly
understand some conflicting data (Figure 1). Moreover, the
complex regulation of cholesterol homeostasis regulation and
its high individual variation could also explain the broad
diversity of clinical symptoms that are shared by the GD and
synucleinopathies.
Transglucosylation activity of the products of GBA genes
has not yet attracted too much attention in what concerns to
the potential link with origin and progression of both PD and
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GD. It is reasonable to hypothesize that hydrolysis (controlling
ceramide and GlcCer levels), and transglucosylation (controlling
GlcChol concentration and function) are both responsible of
some of the clinical traits in GD, in particular those concerning
the heterogeneity of symptoms.
How steryl-glucosides are synthesized? Paradoxically,
different GCases (see below for details) are able to both
hydrolyze and synthesize steryl-glucosides. Synthesis is achieved
by transglucosylation and the short answer is that the enzyme,
located in lysosomes, is likely to be more engaged in hydrolysis
(Akiyama et al., 2011, 2013) whereas GBA2-coded GCase,
which is unrelated to GBA1-coded GCase and not located in
lysosomes, is more likely related to the formation of steryl-
glucosides. The level of steryl-glucosides in a neuron depends
on the balance between the hydrolytic and transglucosylation
activities of these two different proteins, each being coded by
one of two unrelated genes. In other words, sterylglucoside
metabolism is controlled by both GBA1-coded GCase and
by GBA2-coded GCase (see Akiyama et al., 2016; Akiyama
and Hirabayashi, 2017). Hence: (i) the impact of mutations in
the GBA1 gene that are linked to PD increased genetic risk
should be studied in both hydrolysis and transglucosylation
activities, and (ii) alterations/mutations in the GBA2 gene
should be studied in parallel with alterations/mutations in the
GBA1 gene.
In non-pathological steady-state conditions the GBA1 gene
product promotes the degradation of GlcChol. In contrast, in
similar conditions, the GBA2 gene product seems to work in
the opposite direction (GlcChol synthesis). The balance keeping
GlcChol levels within a narrow physiological range may by
altered in pathological situations, even without mutations in
the genes of the enzymes. For both proteins, transglucosylation
is reversible and, accordingly, will proceed in one or another
direction depending on availability of substrates/products. Given
the different subcellular localization of GBA1 and GBA2 and
fluctuations in sterols and sphingolipids that conceivably occur
in healthy and altered neural cells, a disbalance on sphingolipids
and sterol levels may occur. The scenario becomes more complex
upon arrival of cholesterol from lipoproteins or release of
ceramide from sphingomyelin. In those alternative events and in
pathological scenarios GBA-gene-derived enzymes acquire more
relevance.
MECHANISMS OF TOXICITY INDUCED BY
STERYL-GLUCOSIDES
The fact that the balance between GBA1-coded GCase
and GBA2-coded GCase affects the level of glycosyl sterol
derivatives opens several lines of analysis focused on explaining
neurotoxicity underlying mechanisms. Here we highlight just
one that has not been previously contemplated in relationship
with GD-related PD.
The Pink1/parkin pathway, intended to maintain
mitochondrial integrity, is modulated by Akt, a kinase
whose activity is in turn regulated by GlcChol. There is
another important issue related to the ever increasing
concern on the association of mitochondrial dysfunction
and neurodegenerative diseases in general and particularly
when considering synucleinopathies (Cuadrado-Tejedor
et al., 2013; Bose and Beal, 2016; Al Shahrani et al., 2017;
Burbulla et al., 2017; Gao et al., 2017; Liu and Zhu, 2017;
Pech and Verstreken, 2018; Rocha et al., 2018). The content
of cholesterol in mitochondrial membranes is low, something
consistent with the assumed evolutionary origins, namely
symbiotic inclusion of bacteria (whose cholesterol content
in negligible) into eukaryotic cells. Surely, mitochondria
react to cholesterol-derivatives and it has been reported that
GlcChol alters cell respiration and mitochondria-generated
reactive oxygen species (ROS) and respiration (Panov et al.,
2010; Shi et al., 2013). Although the underlying mechanisms
are not known, the effects of GlcChol occur under active
oxidation of succinate and this fact is relevant as it has been
reported that the major source of ROS generation in neuronal
mitochondria is associated with succinate handling by the
electron transport chain (Panov et al., 2009). Combining a
higher ROS production with elevated cholesterol contents
in mitochondria could eventually result in higher levels of
oxysterols that are contributors to the pathophysiology of PD
and both potential biomarkers and therapeutic targets of the
illness (Doria et al., 2016).
CONCLUSIONS AND SUGGESTIONS FOR
ACHIEVING MECHANISTIC INSIGHTS
The link between GBA1 gene mutations and PD is more
likely due to a loss-of-function of GCase activity; loss-of-
function is more usual in congenital diseases affecting enzyme
genes and reduced enzyme activity the main cause of disease-
promoting alterations. The level of sterylglucosides and in
particular of GlcChol, which are toxic upon accumulation, are
controlled by both hydrolysis and transglucosylation activities
of both GBA1e and GBA2e gene products. Consequently,
polymorphisms/mutations in the GBA2 gene should be
studied in PD patients, especially in those already carrying
GBA1 gene mutations. The transglucosylation activity of
proteins encoded by mutated GBA genes should be determined.
As mentioned above, the homeostatic control of synthesis
and degradation of GlcChol is extremely relevant due to their
multiple roles in different cell types and cell compartments.
Transglucosylation may help to find the cause of disease-
promoting alterations by GBA gene mutations. Complexities
surrounding cholesterol homeostasis and patient-to-patient
variation in GCase hydrolytic/transglucosylation activities
could underlie the broad diversity of clinical symptoms in GD
and the complex pattern of disease course and PD clinical
manifestations in PD. Accordingly, it would be also desirable
to measure GlcChol levels in plasma and in cerebrospinal fluid.
To have a reference it would be also very relevant to measure
GlcChol levels in plasma and in post-mortem neurological
tissue of GD type 2 patients (those with sooner neurological
manifestations and reduced life expectancy). A relatively high
level of GlcChol in these patients could reinforce the hypothesis
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of the loss-of-function as mainculprit and could confirm the role
of glucosylated sterols in PD-associated neuropathology.
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